U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Phosphate is a major intracellular anion in mammals. Hydrogen phopshate is a protonated form of phosphate. In serum, phosphate exists in two forms, dihydrogen phosphate (H2PO4) and its salt, mono-hydrogen phosphate (HPO4). At the physiologic pH of 7.40, the pK of H2PO4 is 6.8 and the ratio of HPO4 to H2PO4 is 4:1. Altered level of phosphate can be an indicator of various disorders, such as chronic renal failure, hypoparathyroidism, familial intermittent hyperphosphatemia, endocrine disorders, hyperthyroidism, acromegaly, juvenile hypogonadism, etc. These disorders may lead to either hyper- or hypophosphatemia, which can be caused by cellular shifts of phosphate. Patients with hypophosphatemia can be treated with dietary phosphate supplements (potassium phosphate, for example).

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
PROCALAMINE

Approved Use

ProcalAmine is indicated for peripheral administration in adults to preserve body protein and improve nitrogen balance in well-nourished, mildly catabolic patients who require short-term parenteral nutrition.

Launch Date

3.89664014E11
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Diagnostic
Unknown

Approved Use

Unknown
Diagnostic
Unknown

Approved Use

Unknown
Primary
SODIUM PHOSPHATES INJECTION

Approved Use

Sodium Phosphates Injection, USP, 3mM P/mL, is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (4 mEq/mL) must be calculated into total electrolyte content of such prepared solutions.
PubMed

PubMed

TitleDatePubMed
Diurnal variation in the levels of glucose and related substances in healthy and diabetic subjects during starvation.
1967 Feb
Determination of inorganic phosphate in serum and saliva using a synthetic receptor.
2003 Jun 12
Amperometric biosensor for determining human salivary phosphate.
2005 Aug 15
Phosphorus amendment reduces hepatic and renal oxidative stress in mallards ingesting lead-contaminated sediments.
2006 Jun
Patents

Patents

Sample Use Guides

lose body protein: approximately three liters per day of ProcalAmine will provide a total of 90 grams of amino acids, 390 nonprotein calories and the recommended daily intake of principal intra- and extracellular electrolytes for the stable patient. Therapy can begin with three liters of ProcalAmine on the first day with close monitoring of the patient. As with all intravenous fluid therapy, the goal is to provide adequate water to compensate for insensible, urinary and other losses, and electrolytes for replacement and maintenance. These requirements should be determined frequently and appropriately administered. Additional electrolytes should be administered evenly throughout the day, and irritating medications should be injected at an alternate infusion site. Pediatric Use ProcalAmine is intended for use in adults. Use of ProcalAmine in pediatric patients is governed by the same considerations that affect the use of any amino acid solution in pediatrics. The amount administered is dosed on the basis of grams of amino acids/kg of body weight/day. Two to three g/kg of body weight for infants with adequate calories are generally sufficient to satisfy protein needs and promote positive nitrogen balance. Solutions administered by peripheral vein should not exceed twice normal serum osmolarity (718 mOsmol/L). Venous irritation at an infusion site can be minimized by the selection of a large peripheral vein as well as by slowing the rate of infusion. In pediatric patients, the final solution should not exceed twice normal serum osmolarity (718 mOsmol/L). nausea: for maximum effectiveness never dilute or drink fluids of any kind immediately before or after taking this product. Adults and children 12 years of age and over: one or two tablespoons; children 2 to under 12: one or two teaspoons; repeat dose every 15 minutes or until distress subsides; do not take more than 5 doses in 1 hour without consulting a doctor.
Route of Administration: Other
37% phosphoric acid, 17% EDTA, 10% citric acid, 2% chlorhexidine (solution and gel), and 5.25% NaOCl were tested their antimicrobial activity was tested against Candida albicans, Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Actinomyces meyeri, Parvimonas micra, Porphyromonas gingivalis, and Prevotella nigrescens according to the agar diffusion method. The cytotoxicity of the irrigants was determined by using the MTT assay. Phosphoric acid presented higher antimicrobial activity compared to the other tested irrigants.
Substance Class Mixture
Created
by admin
on Wed Jul 05 23:52:34 UTC 2023
Edited
by admin
on Wed Jul 05 23:52:34 UTC 2023
Record UNII
GR686LBA74
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORM
Common Name English
SODIUM PHOSPHATE, DIBASIC
II   USP  
Preferred Name English
SODIUM PHOSPHATE,DIBASIC
VANDF  
Common Name English
SODIUM PHOSPHATE, DIBASIC [ORANGE BOOK]
Common Name English
SODIUM PHOSPHATE, DIBASIC [USP IMPURITY]
Common Name English
SODIUM PHOSPHATE,DIBASIC [VANDF]
Common Name English
SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED
Common Name English
DIBASIC SODIUM PHOSPHATE
Common Name English
SODIUM PHOSPHATE, DIBASIC [II]
Common Name English
DIBASIC SODIUM PHOSPHATE [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29730
Created by admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
Code System Code Type Description
ChEMBL
CHEMBL1060
Created by admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
PRIMARY
NCI_THESAURUS
C66545
Created by admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
PRIMARY
MESH
C018279
Created by admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
PRIMARY
CAS
10140-65-5
Created by admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
PRIMARY
DAILYMED
GR686LBA74
Created by admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
PRIMARY
EPA CompTox
DTXSID0064969
Created by admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
PRIMARY
EVMPD
SUB12491MIG
Created by admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
PRIMARY
DRUG BANK
DB14502
Created by admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
PRIMARY
FDA UNII
GR686LBA74
Created by admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
PRIMARY
CHEBI
34683
Created by admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
PRIMARY
RXCUI
236719
Created by admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
PRIMARY RxNorm
Related Record Type Details
ACTIVE MOIETY
Definition References